

## **Naturally improving the natural cytotoxicity of natural killer (NK) cells**

Martin Villalba<sup>\*,1,2</sup>, Catherine Alexia<sup>1</sup>, Anais Bellin-Robert<sup>1</sup>, Alexis Fayd'herbe de Maudave<sup>1</sup>  
and Delphine Gitenay<sup>1</sup>

<sup>1</sup> IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.

<sup>2</sup> IRMB, CHU Montpellier, France.

\* corresponding author

E-mail: martin.villalba@inserm.fr

**Running title:** improving natural NK function

## **Abstract**

The innate lymphocyte lineage natural killer (NK) is now the target of multiple clinical applications, although none has received an agreement from any regulatory agency yet. Transplant of naïve NK cells has not proven efficient enough in the vast majority of clinical trials. Hence, new protocols wish to improve their medical use by producing them from stem cells and/or modifying them by genetic engineering. These techniques have given interesting results but these improvements often hide that natural killers are mainly that: natural. We discuss here different ways to take advantage of NK physiology to improve their clinical activity without the need of additional modifications except for *in vitro* activation and expansion and allograft in patients. Some of these tactics include combination with monoclonal antibodies (mAb), drugs that change metabolism and engraftment of specific NK subsets with particular activity. Finally, we propose to use specific NK cell subsets found in certain patients that show increase activity against a specific disease, including the use of NK cell line derived from patients.

**Keywords:** NK cells, microenvironment, monoclonal antibodies (mAbs), antibody-dependent cell cytotoxicity (ADCC), autoimmune diseases, CD45RARO

## **Introduction**

Natural killer (NK) cells are bone marrow derived cytotoxic lymphocytes (CL) that are well equipped for the destruction of target cells without the need for prior antigen stimulation. In peripheral blood, human NK cells are mostly CD3<sup>-</sup>CD56<sup>dim</sup> cells with high cytotoxic activity, while CD3<sup>-</sup>CD56<sup>bright</sup> cells excel in cytokine production (1). Additional markers can be used to identify specific subsets within these NK cell populations (2-4). *In vitro* evidence indicates that CD56<sup>bright</sup> NK cells are precursors of CD56<sup>dim</sup> NK cells and this might also be the case *in vivo* (2). In contrast to T cells, grafted NK cells show short live, low expansion and low alloreactivity such as graft versus host (GVH) in humans. Hence, NK can provide a potential source of allogeneic “off-the-shelf” cellular therapy and mediate major anti-target effects without inducing potentially lethal alloreactivity. Given the multiple unique advantages of NK cells, researchers are now exploring different ways to expand and/or activate them for clinical purposes.

## **NK cells in clinics: the problems**

Researchers working on the clinical use of NK cells have found numerous challenges. First, this cell lineage represents a low percentage of lymphocytes, usually estimated to 5-15%. In addition this changes during human development (3), making the transfer of sufficient allogeneic cells from a single donor to a patient challenging.

Second, NK cells have low lifespans, in average 1 week (4), suggesting that allogenic cells will shortly survive after engraftment. However, these results should be taken with caution. Lifetime studies were performed using deuterium incorporation, and only actively dividing cells incorporate it. Hence, this technique may not account for long-lived, non-dividing cells. Moreover, researchers normally focus on peripheral blood, hence NK cells mainly homing in lymph nodes such as CD56<sup>bright</sup> cells are not taken into account in their real weight (4). But, studies in blood are valid considering that allogeneic NK cells for engraftment are obtained from peripheral blood. Moreover, *in vitro* stimulated NK cells normally gain a mature phenotype despite high CD56 expression (5). Therefore, the previous estimates are a reasonable proxy for the amount of time NK cells will be active after allogenic engraftment. In agreement, the persistence of *ex vivo* haploidentical IL-2-activated and -expanded NK cells ranges between 7 and 10 days in patients with AML, NHL and ovarian cancer (6).

The third challenge is that NK cells show doubling times of 1.25 days after activation (7). This is significantly longer than T cell doubling time during the initial expansion phase, which are 8 and 11 h for CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively (8). Moreover, after allogeneic engraftment

most clinical results failed to show significant expansion of donor NK cells (5,6,9–12). Perhaps the high renew and short lifespan account for these poor *in vivo* expansions because NK cells have already strongly expanded during their maturation and they are prone to “effector-like” phenotype, at least in the blood population.

Fourth, naïve NK cells possess a relatively low activity compare to activated cells (5,13). This could be responsible of the low efficacy of NK cell-mediated therapies (10–12).

Fifth, there are several attempts to activate endogenous NK cells, e.g. by blocking NK cell inhibitory receptors. This led to the development of IPH2101, a killer inhibitory receptors (KIRs)/KIRL blocking antibody (Ab) (14), or monalizumab, a humanized anti-NKG2A Ab (15). This approach has the inconvenience that in cancer patients NK cells are hyporeactive (10,11,16), suggesting that they could be unable to eliminate tumor cells even after releasing KIR inhibition. Moreover, recent clinical data suggest that such antibodies can modify the endogenous NK repertoire and make them further hyporeactive (17). Other clinical attempts to activate endogenous NK cells include the use of lenalidomide (LEN; (18,19)). Biological results from the Phase Ib/II clinical trial GALEN suggest that LEN could facilitate obinutuzumab (OBZ)-mediated NK cell activation (19), as was observed with rituximab (RTX) (20). In fact cancer patients, at least those with hematological cancers, already possess NK cells, which recognize and kill tumor cells, but are unable to control the disease (19,21,22). Why only a fraction of NK cells are fighting against the tumor is unknown. Which is known is that blood-born cancer cells use different mechanisms for immune escape (23,24), e.g. by inducing NK cell dysfunction (25). This mechanism has also been observed in a variety of solid tumor patients (16).

Due to all these adverse points recent clinical approaches target *in vitro* expanded and activated NK cells and hence the use of allogeneic NK cells.

### **Mechanisms of NK cell expansion**

In this context, clinical-grade production of allogeneic NK cells is efficient (26) and NK cell-mediated therapy, including the use of *in vitro* expanded allogeneic NK cells, seems safe (10,12,27–30). However, despite the strong cytolytic potential of expanded NK cells against different tumors *in vitro*, clinical results have been very limited (10–12), e.g. NK are considered highly cytotoxic against AML tumor cells, but their efficacy as monotherapy in the clinic is low (10–12) Moreover, the results using NK cell therapy in animal models of solid tumors or in clinical trials are disappointing, even if NK cells can eliminate the engrafted cell type or the primary tumor cells *in vitro* (10–12). In summary, there is not any expansion protocol that

produces allogeneic NK cells able to efficiently eliminate solid tumor cells *in vivo*. Why NK cells destroy most targets *in vitro* but not *in vivo* is unknown. Tumor cells strongly modify the expression of ligands, which are recognized by NK cell activating or inhibiting receptors when cultured *in vitro* (31). This could lead to the mistrust that those specific tumor cells would be NK sensitive or resistant *in vivo*. Allogeneic NK cells survive for several days in patient's body (see above), hence their initial survival is probably not the blocking step for their efficacy *in vivo*. Impaired tumor infiltration and/or low cytolytic activity in the immunosuppressive tumor environment are usually pointed out as responsible of their low function *in vivo*. Hence, researchers have focused on protocols to activate them enough to bypass these clinical obstacles.

There are many protocols to expand and activate *in vitro* NK cells (5,10,12,27–30). For many clinical uses, the manufactured cells should express the FcγRIIIa, also called CD16. The probably exception is those protocols wishing to generate chimeric antigen receptor (CAR) NK. We have produced umbilical cord blood (UCB)-derived NK cells because they are rapidly available, present low risk of viral transmission and have less strict requirements for HLA matching and lower risk of GvH disease (GvHD)(10). Expansion was driven by Epstein–Barr virus (EBV)-transformed lymphoblastoid B cell lines as accessory cells, which induce a unique NK cell genetic reprogramming (32), generating effectors that overcome the anti-apoptotic mechanism of leukemic cells (33) and that are able to eliminate tumor cells from patients with poor prognosis (34). NK cells obtained with this protocol perform antibody-dependent cell cytotoxicity (ADCC) *in vitro* and *in vivo* with different therapeutic antibodies and against diverse target cells (5).

NK cell expansion is extremely challenging from an industrial point of view (35,36), partly due to the problems described in the previous section. In addition, NK cell production should be easily scaled up and developed with good manufacturing practices (GMP). Several biotech companies are now producing NK cell-based products that could reach the clinic in the future (36). We will discuss now mechanisms to naturally improve NK cytotoxicity. We will not discuss about lympho-depleting chemotherapy, e.g. cyclophosphamide followed by daily fludarabine, which is already largely use in clinics prior to NK cell infusion (37).

### **Cytokines mediate NK activation**

Generally, when NK will reach the target microenvironment they will receive a burst of cytokines from other cells, e.g. those immune cells that have already infiltrated the tumor. These cytokines affect NK cell behavior and activation and has extensively been reviewed elsewhere

(38). Hence, we will only briefly describe some few uses. IL-2 and IL-15 are strong NK cell activators, but their clinical use *in vivo* is challenging due to their toxicity (36). Moreover, IL-2 expands and mobilizes regulatory T cells, which dampen the activity of several effector cells including NK (36). IL-15, although less toxic than IL-2, is limited by its short half-life leading to poor functional activity *in vivo*. However, *in vitro* both cytokines are very efficient stimuli to activate and expand NK cells (5,32). In fact, membrane-bound IL-15 is currently the best activating cytokine (39), although membrane-bound IL-21 is becoming an interesting challenger (40,41). In any case, long-term cytokine treatment can lead to NK cell exhaustion, which will inhibit NK activity (42).

### **Modifying the target microenvironment**

Tumor cells, directly or by controlling non-transformed cells, modify the environment to make it immunosuppressive and avoid destruction by effector immune cells (23,24,42). These modifications include metabolic changes with the production of metabolites that negatively affect NK cell cytotoxicity, e.g. lactate (24,42). This is the classical metabolite produced by tumor cells under the Warburg effect: cells perform glycolysis even in the presence of ample oxygen (24). To recover the reducing power of  $\text{NAD}^+$ , which has been reduced to  $\text{NADH}^+\text{-H}^+$  during glycolysis, cells reduce pyruvate creating lactate. This mechanism recovers the cell reducing power and allows the glycolysis to proceed. During the Warburg effect, the products that are not oxidized, i.e. that are not consumed to produce  $\text{CO}_2$ , serve to create new intermediate metabolites that are used for anabolism. But in addition, tumor cells release lactate to the external medium. This acidifies the environment and inhibits the antitumor response of CLs because the killing activity of these cells is extremely sensitive to the decrease in pH (42,43). There are some compounds such as dichloroacetate (DCA) or metformin that inhibit the Warburg effect and block lactate production (24,44,45). It is hence conceivable that such drugs could increase the cytolytic activity of NK, or other CLs, *in vivo*.

In contrast, during the killing of yeast cells or cryptococcoma, NK cells appeared to profit from the acidic pH of the microenvironment by displaying enhanced perforin degranulation and killing capacity (43). Therefore, an interesting possibility would be to modify the NK-tumor environment to match that of NK-yeast cells/cryptococcoma in order to increase NK cytotoxicity even at low pH.

Another way to increase NK activity would be to decrease adenosine concentration in tumor environment. This nucleotide is found as much as 100-fold higher in tumors than in normal tissues and contributes to immune evasion by inhibiting for example NK cell cytolytic activity

(42). The ectonucleotidases CD39 and CD73 produce large amounts of adenosine, hence their inhibition decreases tumor growth and metastasis. This type of treatment has reached the clinic with the anti-CD73 antibody Oleclumab (42).

Several vitamins, e.g. A, C and E, induce changes in NK cell markers associated to activation (46). Vitamin A/retinoic acid increases target expression of natural-killer group 2, member D (NKG2D) ligands in mouse, RAE-1 (46), and humans, MICA/B (47,48). However, it can activate (46,48) or inhibit (32,46,49) NK activity depending on the cellular context. Hence, their use in clinics must be carefully studied.

### **ADCC is natural: NK cells and mAbs**

Cell-mediated immune defense includes ADCC. NK only harbor the activating Fc $\gamma$  receptors CD16a and Fc $\gamma$ RIIc, also known as CD32c. This gives NK a preponderant role in ADCC in humans (50). Although not include in the so-called “natural NK cytotoxicity”, ADCC is totally a natural physiological process mediated, at least in large part, by NK cells, but involving coordination and crosstalk of different immune cells (50). Through ADCC NK cells can modulate the adaptive immune response and generate long term protection (51).

Differential response to therapeutic mAbs has been reported to correlate with a specific polymorphism in *CD16* (V158F) (52). This polymorphism is associated with differential affinity for mAbs (50). Indeed Fc $\gamma$ Rs variant play an important role in determining prognosis of monoclonal IgG antibodies (mAbs) therapy (53). Hence, an obvious possibility is using NK cell from donors with the 158V polymorphism, which shows increase affinity for Fc and better prognosis to mAb treatment (50,53). This engrafted NK should show improved activity after transplantation, mainly when associated to mAb cotherapy. Conversely, different approaches modify the antibody Fc region to increase patient NK cell activity. For example, obinutuzumab, an anti-CD20 mAb, is afucosylated to increase CD16 binding and thereby enhance its ADCC activity (54).

### **Arming NK cells**

As previously described NK cells recognize antibody-opsonized target cells and hence take advantage of the exquisite selectivity of mAb to generate a discriminatory immune response against target cells. An interesting possibility of increasing NK function is loading mAbs into the NK CD16 Fc receptor, giving them an exogenous selectivity against target cells. Recent data show that expanded NK retain RTX on their CD16 at least overnight (5). Moreover, RTX-armed NK show improved cytolytic activity compared to non-armed NK cells. In fact, *in vitro*

results using RTX and CD20<sup>+</sup> tumor cells derived from chronic lymphocyte leukemia (CLL) patients do not show any differences on NK cell-mediated ADCC between opsonizing targets or “arming” NK (5).

There are other possibilities to “arm” expanded NK cells, e.g. i) with activating receptors that enhance their natural anti-tumor capacity; ii) with chimeric antigen receptors (CAR) that can redirect them towards specific tumor targets (37) or iii) with death receptor ligands such as a glycosylated form of TNF-related apoptosis-inducing ligand (TRAIL) fusion protein (55). These armed NK cells show improved antitumor function, but these approaches require genetic modification of NK cells, and we do not consider them “natural”.

### **Recovering NK activity in autoimmune diseases by replacing endogenous NK cells**

NK cells from patients of several autoimmune diseases present populations that can contribute to disease progression. In other cases, endogenous NK cells are defective, e.g. in cytotoxicity, due to genetic or environmental facts. Hence, engrafting NK subsets with proper activity could rescue NK activity and improve prognosis. Below we discuss some specific diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE). However similar approaches could also target type I diabetes (T1D) and Sjögren’s syndrome (56).

RA patients accumulate immature NK cells in damaged joints. Sinovial fluid (SF) NK (sfNK) cells derived from these patients are enriched in the CD56<sup>bright</sup> population (57). Moreover, sfNK produce more IFN $\gamma$  and TNF $\alpha$  after interleukin-15 activation (57,58). IL-15, which is present in the SF of RA patients, correlates with disease severity and is important in disease progression (59). Hence all this may contribute to the production of proinflammatory cytokines and long-term inflammation (56). The sfNK cell subset, high CD56, CD94/NKG2A, CD69 and NKp44 and low CD16, is unlike any population documented in any other organ and is enriched in patients with erosive deformative RA (DRA) (57,58). The percentage of total NK cells was doubled in the peripheral blood and tripled in SF of DRA, as compared to non-deformative RA (NDRA), patients (58). Other characteristics of these sfNK in RA are almost absent KIR expression, low CD57 and high natural killer cell p46-related protein (NKp46) (58). Probably the chemokine receptors specifically expressed by immature NK cells facilitate their infiltration into the damaged joints and favor RA damage exacerbation (58). Interestingly, the sfNK CD56<sup>bright</sup> population express CD16, something that is unique, although its functionality was not investigated (58). Since sfNK may play an important role in destruction of joints, which should implicate their IFN $\gamma$  and TNF $\alpha$  production, it would be interesting to replace the



immature sfNK with mature CD56<sup>dim</sup> cells. An interesting possibility is using those protocols to produce *in vitro* expanded NK cells described earlier. Although these NK cells present high CD56 levels, they possess all characteristics of mature and activated NK such as KIR and NKG2D expression, e.g. (5). The engraft of these cells in damaged joints could reverse the damaging effect of the autologous CD56<sup>bright</sup> cells.

MS is an autoimmune inflammatory disease affecting the central nervous system (CNS). Autoreactive CD4 T cells targeting myelin components are critical mediators. NK cells can control inflammation by killing activated, autoimmune, T cells (56). Activated T cells increase expression of the death-receptor Fas. In patients in remission, NK highly express Fas ligand (FasL), which can eliminate autoreactive T cells through Fas/FasL interactions (60).

During relapse the FasL<sup>high</sup> NK population is lost (60). The site of autoimmunity, i.e. the cerebrospinal fluid, is enriched in immature CD56<sup>bright</sup> NK subset, whereas this population is reduced in peripheral blood (61). Daclizumab, an anti-IL-2R $\alpha$  antibody, ameliorates CNS lesions with a decrease in blood CD4 T cells and increase in blood CD56<sup>bright</sup> NK (62). Hence, current knowledge on the biology of MS suggest that engraftment of a mature, cytolytic, CD56<sup>dim</sup> subset could facilitate elimination of autoreactive T cells. Although a possible negative effect can not be ruled out due to the presence of NKG2D ligands in oligodendrocytes, astrocytes and microglia (56).

SLE is an autoimmune disorder characterized by production of autoantibodies against DNA and nuclear proteins. Like in RA, there is a polyclonal B-cell activation and expansion. NK cell deficiency correlates with SLE in humans and in mouse models of the disease (56). Again, SLE patients show an increase in the proportion of blood CD56<sup>bright</sup> NK cells (63). In addition, NK-dependent cytotoxicity decreases (56). Interestingly in pediatric patients, who show the same NK defects (64), the impaired activity is observed at diagnosis (64). Like in previous described autoimmune diseases reconstitution of a mature CD56<sup>dim</sup> population in SLE patients could improve their prognosis. These approaches requiring the engraftment of “missing” NK cell subsets need proper allogeneic NK recruitment into the target organ. An obvious solution is local engraftment. Another possibility is using a chemokine cocktail. The two NK cell subsets, i.e. CD56<sup>bright</sup> and CD56<sup>dim</sup>, differentially express various chemokine receptors, which attract them to distinct organs (56,59). Hence, locally playing with different chemokines should naturally facilitating the recruitment of a specific subset. In anyway, reconstitution of NK cell activity in periphery should improve patient prognosis in these diseases heavily dependent on NK cell function.

### **Naturally occurring antitumor NK cells: trogocytosis and the CD45RARO paradigm**

The NK cell population with antitumor activity has recently been identified (19,21,22). In multiple hematological cancer patients there is a population of highly activated CD56<sup>dim</sup>CD16<sup>+</sup> NK cells that have recently degranulated, evidence of killing activity. These cells generally expressed Nkp46, NKG2D and KIRs, whereas expression of NKG2A and CD94 is diminished. They are also characterized by a high metabolic activity and active proliferation. Notably, these NK cells carry, non-NK, tumor cell antigens on their surface, evidence of trogocytosis during tumor cell killing, i.e. they carry CD19 in B cell-derived cancers and CD14 in myeloid-derived cancers (19,21,22). The antitumor NK cells are distinguished by their CD45RA<sup>+</sup>RO<sup>+</sup> phenotype, as opposed to non-activated cells in patients or in healthy donors displaying a CD45RA<sup>+</sup>RO<sup>-</sup> phenotype (19,21,22). Therefore antitumor NK cells exist (21). Hence, there is the possibility of selectively expand this population. However, *in vitro* expansion does not really produce similar phenotypes to those found in cancer patients. Moreover, NK cell markers change *in vitro* (21,22). Another possibility would be to exchange the antitumor population of two cancer patients. Notably, CD45RARO cells show strong activity against a different tumor cell (21). This is reminiscent with previous *in vitro* studies showing that NK cells exhibited enhanced cytotoxicity after a prior co-culture with some tumor cells (65,66). But the *in vivo* interest of using patient CD45RARO cells to treat other patients goes further that this possible “priming” effect. It is known that tumor cells have been immune sculpted by the host immune system (67). This allows them to immune escape and generate cancers. However, the mechanisms of tumor immune escape are usually different between host/tumor pairs. This suggests that tumors will be better recognized by antitumor NK cells of another patient, supporting the exchange of NK cells between patients. Obviously, the national health agencies should carefully examine this possibility.

### **Memory NK cells**

In contrast to cancer patients, CD45RARO populations have not been described in patients with viral infections yet (21,22). However, viral-infected patients have NK subsets that are associated to antiviral immunity and could be used for clinical purposes. Human cytomegalovirus (HCMV) infection promotes expansion of NKG2C<sup>+</sup> NK cells with memory-like properties (68,69). Furthermore, NK cells expressing high levels of NKG2C and CD57 are associated with prior HCMV infection. Certain cytokines such as IL-12, which is produced by CD4<sup>+</sup> monocytes, are mandatory for NKG2C<sup>+</sup> cell expansion (70). However there is a lack of

evidence concerning their specific effect against HCMV itself or if there is a recall response to HCMV reactivation (71).

These HCMV-specific NK cells can originate from CD16-induced memory-like NK cells and hence they can be waked up by HCMV antibodies (72). Once activated, these cells could not only attack HCMV-infected cells, but also other NK cell targets such as transformed cells. Subsequently, they could be transferred to patients lacking them to generate the desired immunity. Direct transfer of anti-HCMV antibodies would probably not work because these antibodies presumably do not mediate in the initial generation of NKG2C<sup>+</sup> “adaptive” NK cells in HCMV-seronegative individuals (73).

Another possibility is generating “memory”-like NK cells by incubation with different cytokine cocktails, e.g. IL-2/IL-15/IL-18 (71,72). Some of these cytokines are already part of the current cocktails to amplify and activate human NK cells *in vitro* as described earlier. In fact, several of these protocols also used accessory, target, cells to drive NK cell expansion and/or activation. The target cell contact-dependent priming signals to enhance NK cell activation has already been described, although the priming stimulus is unknown (72). This has not stopped their clinical test in clinics (11).

In summary, exploiting NK cells with memory-like properties might increase the efficacy of these cells and help their clinical development. However, it is uncertain if current protocols to produce *in vitro* expanded NK cells are not really generating “memory-like” NK cells, and hence, the use of “memory-like” NK cell is perhaps already used in clinical studies.

### **NK cell lines: are they natural?**

The difficulties for purify, isolate, expand and transduce primary NK cells for therapeutic applications led researchers to also focus on NK-cell lines such as NK-92 (NK-92® ATCC® CRL-2407™ and NK-92® MI ATCC® CRL-2408™). There are other NK cell lines, but their antitumor cytotoxicity is questioned (74). In any case, our discussion here on NK-92 cells should be valid for new NK cell lines that could reach the clinic. NK-92 phenotype is CD3<sup>-</sup>CD56<sup>+</sup>CD16<sup>-</sup> and display cytotoxicity against a wide range of human primary leukemias, e.g. B-ALL and CML and leukemic cell lines *in vitro* and in SCID mouse models (75). Stable expression of mouse and human CD16 gives ADCC to NK-92 cells and generates the cell lines NK-92<sup>mCD16</sup> and NK-92<sup>hCD16</sup>, respectively (76). In addition, they are a renewable resource to generate CAR-NK-92 cells. In line with our previous comments we will not discuss about these transduced cells. In contrast, non-modified NK cell lines show therapeutic effect without the need of genetic modifications (74). However, transformed cell lines present worries,

such as uncontrolled growth, which require irradiation before infusion into patients. This suppress cell proliferation while, hopefully, maintaining enough cell cytotoxic activity. NK-92 cells have completed phase I trials in cancer patients, e.g. NCT00900809 and NCT00990717. Results show that irradiated NK-92 cells are safe even at very high doses with minimal toxicity in patients with refractory blood cancers (77). In addition, they show clinical benefits with 2 out of 12 patients showing complete response (77).

## **Conclusion**

In a challenging clinical environment with the arrival of “new” cell-therapy products, NK present several advantages and inconveniences. Their clinical improvement by “natural” means that can easily be accepted by natural agencies will greatly favor their use.

## **Abbreviations**

ADCC: antibody-dependent cell-mediated cytotoxicity; AML: acute myeloid leukemia; B-CLL: B-cell chronic lymphocytic leukemia; B-NHL: B-cell non-Hodgkin’s lymphoma; BCL: B-cell lymphoma; DLBCL: Diffuse large B-cell lymphoma; EBV: Epstein–Barr virus; EGFR: epidermal growth factor receptor; e-NK: expanded NK cells; FL: follicular lymphoma; GMP: good manufacturing practices; GvHD: graft-versus-host disease; HSCT: hematopoietic stem cell transplantation; LEN: lenalidomide; mAbs: monoclonal antibodies; NCRs: natural cytotoxicity receptors; NK cells: natural killer cells; OBZ: obinutuzumab; PFS: progression-free survival; RTX: rituximab; UCB: umbilical cord blood; UCBT: umbilical cord blood transplantation;

## **Acknowledgements**

We acknowledge the imaging facility MRI, member of the national infrastructure France-BioImaging supported by the French National Research Agency (ANR-10-INBS-04, «Investments for the future»).

## **Funding**

This work was supported by the PRT-K program 2018 (MV; 2018-021); the “Investissements d’avenir” Grant LabEx MAbImprove: ANR-10-LABX-53 (GC/PM/BR); and Canceropole GSO Emergence (MV; 2018/2019).

**Competing interests**

The authors declare no competing interests.

## References

1. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, Wood SM. Molecular mechanisms of natural killer cell activation. *J Innate Immun* (2011) **3**:216–26. doi:10.1159/000325265
2. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, Moretta L. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. *Cytom A* (2013) **83**:702–13. doi:10.1002/cyto.a.22302
3. Mahapatra S, Mace EM, Minard CG, Forbes LR, Vargas-Hernandez A, Duryea TK, Makedonas G, Banerjee PP, Shearer WT, Orange JS. High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults. *PLoS One* (2017) **12**:e0181134. doi:10.1371/journal.pone.0181134
4. Strauss-Albee DM, Blish CA. Human NK Cell Diversity in Viral Infection: Ramifications of Ramification. *Front Immunol* (2016) **7**:66. doi:10.3389/fimmu.2016.00066
5. Sanchez-Martinez D, Allende-Vega N, Orecchioni S, Talarico G, Cornillon A, Vo DN, Rene C, Lu z-y, Krzywinska E, Anel A, et al. Expansion Of Allogeneic NK Cells With Efficient Antibody-Dependent Cell Cytotoxicity Against Multiple Tumor Cells. *Theranostic* (2018) **8**:3856–3869. doi:10.7150/thno.25149
6. Shevtsov M, Multhoff G. Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. *Front Immunol* (2016) **7**:492. doi:10.3389/fimmu.2016.00492
7. Liu Y, Wu H-W, Sheard MA, Sposto R, Somanchi SS, Cooper LNJ, Lee DA, Seeger RC. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. *Clin Cancer Res Off J Am Assoc Cancer Res* (2013) **19**:2132–2143. doi:10.1158/1078-0432.CCR-12-1243
8. De Boer RJ, Homann D, Perelson AS. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. *J Immunol Baltim Md 1950* (2003) **171**:3928–3935.
9. Anel A, Aguilo JI, Catalan E, Garaude J, Rathore MG, Pardo J, Villalba M. Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity. *Front Immunol* (2012) **3**:187. doi:10.3389/fimmu.2012.00187
10. Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. *Front Immunol* (2017) **8**:329. doi:10.3389/fimmu.2017.00329
11. Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, Grace S, Lowdell MW. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. *PLoS One* (2015) **10**:e0123416. doi:10.1371/journal.pone.0123416
12. Moretta L, Pietra G, Vacca P, Pende D, Moretta F, Bertaina A, Mingari MC, Locatelli F, Moretta A. Human NK cells: From surface receptors to clinical applications. *Immunol Lett* (2016) **178**:15–9. doi:10.1016/j.imlet.2016.05.007
13. Sanchez-Martinez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martinez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, et al. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. *Int J Biochem Cell Biol* (2014) **49**:42–52. doi:10.1016/j.biocel.2014.01.003
14. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood* (2012) **120**:4317–23. doi:10.1182/blood-2012-06-437558
15. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that

- Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. *Cell* (2018) **175**:1731-1743.e13. doi:10.1016/j.cell.2018.10.014
16. Hu z. Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer. *J Immune Based Ther Vaccines Antimicrob* (2013) **2**:1–8.
  17. Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW. Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. *Clin Cancer Res* (2016) **22**:5211–5222. doi:10.1158/1078-0432.CCR-16-1108
  18. Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. *Oncotarget* (2017) **8**:24031–24044. doi:10.18632/oncotarget.15234
  19. Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, Tarte K, Cartron G, Villalba M. NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. *Oncoimmunology* (2018) **7**:e1409322. doi:10.1080/2162402X.2017.1409322
  20. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. *Blood* (2015) **126**:50–60. doi:10.1182/blood-2015-01-625004
  21. Krzywinska E, Allende-Vega N, Cornillon A, Vo DN, Cayrefourcq L, Panabieres C, Vilches C, Déchanet-Merville J, Hicheri Y, Rossi J-F, et al. Identification of anti tumor cells carrying natural killer (NK) cell antigens in patients with hematological cancers. *EBioMedicine* (2015) **2**:1364–1376.
  22. Krzywinska E, Cornillon A, Allende-Vega N, Vo DN, Rene C, Lu ZY, Pasero C, Olive D, Fegueux N, Ceballos P, et al. CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. *PLoS One* (2016) **11**:e0150434. doi:10.1371/journal.pone.0150434
  23. Villalba M, Lopez-Royuela N, Krzywinska E, Rathore MG, Hipskind RA, Haouas H, Allende-Vega N. Chemical metabolic inhibitors for the treatment of blood-borne cancers. *Anticancer Agents Med Chem* (2014) **14**:223–32.
  24. Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N. From tumor cell metabolism to tumor immune escape. *Int J Biochem Cell Biol* (2013) **45**:106–13. doi:10.1016/j.biocel.2012.04.024
  25. Baier C, Fino A, Sanchez C, Farnault L, Rihet P, Kahn-Perles B, Costello RT. Natural Killer Cells Modulation in Hematological Malignancies. *Front Immunol* (2013) **4**:459. doi:10.3389/fimmu.2013.00459
  26. McKenna DH, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. *Transfusion (Paris)* (2007) **47**:520–8.
  27. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* (2005) **105**:3051–7.
  28. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. *Curr Opin Oncol* (2007) **19**:142–7.
  29. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. *J Clin Oncol* (2010) **28**:955–9.
  30. McKenna DH, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S,

- Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. *Transfusion (Paris)* (2007) **47**:520–8.
31. Haspels HN, Rahman MA, Joseph JV, Gras Navarro A, Chekenya M. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions. *Front Immunol* (2018) **9**:1345. doi:10.3389/fimmu.2018.01345
  32. Sanchez-Martinez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martinez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, et al. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. *Int J Biochem Cell Biol* (2014) **49**:42–52. doi:10.1016/j.biocel.2014.01.003
  33. Sanchez-Martinez D, Azaceta G, Muntasell A, Aguilo N, Nunez D, Galvez EM, Naval J, Anel A, Palomera L, Vilches C, et al. Human NK cells activated by EBV lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. *Oncoimmunology* (2015) **4**:e991613. doi:10.4161/2162402X.2014.991613
  34. Sanchez-Martinez D, Lanuza PM, Gomez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martinez-Lostao L, Villalba M, et al. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. *Front Immunol* (2016) **7**:454. doi:10.3389/fimmu.2016.00454
  35. Chabannon C, Mfarrej B, Guia S, Ugolini S, Devillier R, Blaise D, Vivier E, Calmels B. Manufacturing Natural Killer Cells as Medicinal Products. *Front Immunol* (2016) **7**:504. doi:10.3389/fimmu.2016.00504
  36. Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. *Front Immunol* (2017) **8**:631. doi:10.3389/fimmu.2017.00631
  37. Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. *Cytotherapy* (2016) **18**:1422–1434. doi:10.1016/j.jcyt.2016.06.013
  38. Wu Y, Tian Z, Wei H. Developmental and Functional Control of Natural Killer Cells by Cytokines. *Front Immunol* (2017) **8**:930. doi:10.3389/fimmu.2017.00930
  39. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SMH, Coustan-Smith E, Imai C, Campana D. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. *Blood* (2014) **124**:1081–1088. doi:10.1182/blood-2014-02-556837
  40. Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. *Cytotherapy* (2016) **18**:653–663. doi:10.1016/j.jcyt.2016.02.006
  41. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. *PLOS ONE* (2012) **7**:e30264. doi:10.1371/journal.pone.0030264
  42. Chambers AM, Lupo KB, Matosevic S. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells. *Front Immunol* (2018) **9**: doi:10.3389/fimmu.2018.02517
  43. Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, Tuccitto A, Tagliabue E, Castelli C, Rivoltini L. Cancer acidity: An ultimate frontier of tumor immune escape and a



- novel target of immunomodulation. *Semin Cancer Biol* (2017) **43**:74–89.  
doi:10.1016/j.semcancer.2017.03.001
44. Charni S, de Bettignies G, Rathore MG, Aguilo JI, van den Elsen PJ, Haouzi D, Hipskind RA, Enriquez JA, Sanchez-Beato M, Pardo J, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. *J Immunol* (2010) **185**:3498–503.
  45. Catalán E, Charni S, Jaime P, Aguiló J-I, Enríquez J-A, Naval J, Pardo J, Villalba M, Anel A. MHC-I modulation due to metabolic changes regulates tumor sensitivity to CTL and NK cells. *Oncoimmunology* (2015) **4**:e985924. doi:10.4161/2162402X.2014.985924
  46. Grudzien M, Rapak A. Effect of Natural Compounds on NK Cell Activation. *J Immunol Res* (2018) **2018**:4868417. doi:10.1155/2018/4868417
  47. Kim CH. Control of Innate and Adaptive Lymphocytes by the RAR-Retinoic Acid Axis. *Immune Netw* (2018) **18**:e1. doi:10.4110/in.2018.18.e1
  48. Fan X-Y, Wang P-Y, Zhang C, Zhang Y-L, Fu Y, Zhang C, Li Q-X, Zhou J-N, Shan B-E, He D-W. All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion. *Sci Rep* (2017) **7**:16481. doi:10.1038/s41598-017-16745-z
  49. Oliveira L de M, Teixeira FME, Sato MN. Impact of Retinoic Acid on Immune Cells and Inflammatory Diseases. *Mediators Inflamm* (2018) doi:10.1155/2018/3067126
  50. Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. *Ann Transl Med* (2019) **7**:105. doi:10.21037/atm.2019.01.42
  51. Michaud H-A, Eliaou J-F, Lafont V, Bonnefoy N, Gros L. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. *Oncoimmunology* (2014) **3**:e955684. doi:10.4161/21624011.2014.955684
  52. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood* (2002) **99**:754–8.
  53. Mellor JD, Brown MP, Irving HR, Zalcborg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. *J Hematol Oncol J Hematol Oncol* (2013) **6**:1. doi:10.1186/1756-8722-6-1
  54. Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? *Blood* (2017) **130**:581–589. doi:10.1182/blood-2017-03-771832
  55. Song X, Hong S-H, Kwon WT, Bailey LM, Basse P, Bartlett DL, Kwon YT, Lee YJ. Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft. *Mol Cancer Ther* (2016) **15**:1591–1601. doi:10.1158/1535-7163.MCT-15-0937
  56. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. *Arthritis Res Ther* (2013) **15**:216. doi:10.1186/ar4232
  57. Dalbeth N, Callan MFC. A subset of natural killer cells is greatly expanded within inflamed joints. *Arthritis Rheum* (2002) **46**:1763–1772. doi:10.1002/art.10410
  58. Yamin R, Berhani O, Peleg H, Aamar S, Stein N, Gamliel M, Hindi I, Scheiman-Elazary A, Gur C. High percentages and activity of synovial fluid NK cells present in patients with advanced stage active Rheumatoid Arthritis. *Sci Rep* (2019) **9**:1351. doi:10.1038/s41598-018-37448-z
  59. Yap H-Y, Tee SZ-Y, Wong MM-T, Chow S-K, Peh S-C, Teow S-Y. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development. *Cells* (2018) **7**: doi:10.3390/cells7100161
  60. Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, Yamamura

- T. Natural killer type 2 bias in remission of multiple sclerosis. *J Clin Invest* (2001) **107**:R23-29. doi:10.1172/JCI11819
61. Hamann I, Dörr J, Glumm R, Chanvillard C, Janssen A, Millward JM, Paul F, Ransohoff RM, Infante-Duarte C. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. *J Neuroimmunol* (2013) **254**:165–169. doi:10.1016/j.jneuroim.2012.08.009
62. Bielekova B, Catalfamo M, Reichert-Scriver S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2/Ralpha-targeted therapy (daclizumab) in multiple sclerosis. *Proc Natl Acad Sci U S A* (2006) **103**:5941–5946. doi:10.1073/pnas.0601335103
63. Schepis D, Gunnarsson I, Eloranta M-L, Lampa J, Jacobson SH, Kärre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. *Immunology* (2009) **126**:140–146. doi:10.1111/j.1365-2567.2008.02887.x
64. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawai H, Komiyama A. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. *J Rheumatol* (1996) **23**:171–177.
65. North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, Anderson R, Lowdell MW. Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation. *J Immunol* (2007) **178**:85–94. doi:10.4049/jimmunol.178.1.85
66. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. *Blood* (2010) **115**:605–14.
67. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* (2002) **3**:991–8.
68. Lopez-Botet M, Vilches C, Redondo-Pachon D, Muntasell A, Pupuleku A, Yelamos J, Pascual J, Crespo M. Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. *Front Immunol* (2017) **8**:166. doi:10.3389/fimmu.2017.00166
69. Gumá M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A, López-Botet M. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. *Blood* (2006) **107**:3624–3631. doi:10.1182/blood-2005-09-3682
70. Rölle A, Pollmann J, Ewen E-M, Le VTK, Halenius A, Hengel H, Cerwenka A. IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. *J Clin Invest* (2014) **124**:5305–5316. doi:10.1172/JCI77440
71. Peng H, Tian Z. Natural Killer Cell Memory: Progress and Implications. *Front Immunol* (2017) **8**:1143. doi:10.3389/fimmu.2017.01143
72. Pahl JHW, Cerwenka A, Ni J. Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors. *Front Immunol* (2018) **9**: doi:10.3389/fimmu.2018.02796
73. Capuano C, Battella S, Pighi C, Franchitti L, Turriziani O, Morrone S, Santoni A, Galandrini R, Palmieri G. Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming. *Front Immunol* (2018) **9**: doi:10.3389/fimmu.2018.01031
74. Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells. *Front Immunol* (2016) **7**: doi:10.3389/fimmu.2016.00091
75. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ. Antileukemia activity of a natural killer cell line against human leukemias. *Clin Cancer Res* (1998) **4**:2859–2868.

76. Clémenceau B, Vivien R, Pellat C, Foss M, Thibault G, Vié H. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. *mAbs* (2013) **5**:587–594. doi:10.4161/mabs.25077
77. Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang X-H, Chaboureau A, Viswanathan S, Keating A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. *Oncotarget* (2017) **8**:89256–89268. doi:10.18632/oncotarget.19204